Classes
DEA Class; Rx
Common Brand Names; ZINBRYTA
- Interleukin-2 (IL-2) Inhibitors
MS Agents
Description
Immunosuppressant; chimeric monoclonal antibody (IgG1)
Previously approved for relapsing forms of muiltiple sclerosis
Withdrawn form the worldwide market due to safety concerns, including brain inflammation, hepatotoxicity, and other immune-mediated disorders
Indications
Indicated for the treatment of relapsing forms of multiple sclerosis.
Contraindications
Daclizumab (Zinbryta) was withdrawn from the worldwide market in March 2018 due to safety concerns.
Adverse Effects
- Neutropenia
- Fever
- Nausea
- Vomiting
- Anorexia
- Abdominal discomfort or pain
- Diarrhea
- Hemorrhagic colitis
- Oral mucosal ulceration
- Jaundice
- Alopecia
- Skin rash
- Pigmentation of skin and changes in nails
Warnings
—
Pregnancy and Lactation
There are no adequate data on the developmental risk associated with daclizumab use in pregnancy.
There is no information regarding the presence of daclizumab in human milk, the effects on the breast-fed infant, or the effects on milk production.
Maximum Dosage
The suggested maximum tolerated dose (MTD) for cyclophosphamide is dependent on the disease state, performance status, and other chemotherapy agents or radiation therapy given in combination.
In conjunction with bone marrow transplantation, 240 mg/kg IV over a 4 day period (60 mg/kg/day IV) or 7 g/m2 (240 mg/kg) IV as a 96-hour continuous infusion have been reported as the MTD with acceptable myelosuppression and dose-limiting cardiotoxicity. Orally, 50 mg/m2/day PO for 14 days has been reported as the MTD.
In conjunction with bone marrow transplantation, 240 mg/kg IV over a 4 day period (60 mg/kg/day IV) or 7 g/m2 (240 mg/kg) IV as a 96-hour continuous infusion have been reported as the MTD with acceptable myelosuppression and dose-limiting cardiotoxicity. Orally, 50 mg/m2/day PO for 14 days has been reported as the MTD.
50 mg/kg IV in divided doses over a period of 2—5 days; 5 mg/kg/day PO.
50 mg/kg IV in divided doses over a period of 2—5 days; 5 mg/kg/day PO.
How supplied
Daclizumab
ZINBRYTA Subcutaneous Inj Sol: 1mL, 150mg
